Margaux Lasseigne focuses her practice on life sciences matters. She regularly advises clients from the life sciences and healthcare sector (pharmaceutical drugs, medical devices, cosmetics), particularly in market access, promotional activities, compliance and commercial matters. She also regularly provides national security guidance to clients whose transactions may require foreign direct investment (FDI) review in the EU and internationally.

Prior to joining Dechert as an associate, Margaux Lasseigne served as intern at Dechert, as well as another international law firm.

    • The legal framework for parallel distribution finally clarified! – L’Usine Nouvelle (September 24, 2021)
    • Reforming early access to medicines: simplifying and tightening the criteria – L’Usine Nouvelle (April 13, 2021)